257 related articles for article (PubMed ID: 12857431)
1. Absence of profound hyperinsulinism in polycystic ovary syndrome is associated with subtle elevations in the plasminogen activator inhibitor system.
Sills ES; Drews CD; Perloe M; Tucker MJ; Kaplan CR; Palermo GD
Gynecol Endocrinol; 2003 Jun; 17(3):231-7. PubMed ID: 12857431
[TBL] [Abstract][Full Text] [Related]
2. Plasminogen activator inhibitor activity, 4G5G polymorphism of the plasminogen activator inhibitor 1 gene, and first-trimester miscarriage in women with polycystic ovary syndrome.
Glueck CJ; Sieve L; Zhu B; Wang P
Metabolism; 2006 Mar; 55(3):345-52. PubMed ID: 16483878
[TBL] [Abstract][Full Text] [Related]
3. [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases].
Song J; Shen H; Li J; Huang Z; Zhang Y
Zhonghua Fu Chan Ke Za Zhi; 2002 Feb; 37(2):86-9. PubMed ID: 11953071
[TBL] [Abstract][Full Text] [Related]
4. Comparison of fibrinolytic and metabolic system parameters in obese patients with polycystic ovary syndrome and women with simple obesity.
Słopień R; Lewandowski K; Kolacz E; Zawilska K; Warenik-Szymankiewicz A
Gynecol Endocrinol; 2006 Nov; 22(11):651-4. PubMed ID: 17145652
[TBL] [Abstract][Full Text] [Related]
5. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome.
Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R
Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572
[TBL] [Abstract][Full Text] [Related]
6. Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome.
Carmassi F; De Negri F; Fioriti R; De Giorgi A; Giannarelli C; Fruzzetti F; Pedrinelli R; Dell'Omo G; Bersi C
Thromb Res; 2005; 116(3):207-14. PubMed ID: 15935829
[TBL] [Abstract][Full Text] [Related]
7. Levels of lipoprotein and homocysteine in non-obese and obese patients with polycystic ovary syndrome.
Yilmaz M; Biri A; Bukan N; Karakoç A; Sancak B; Törüner F; Paşaoğlu H
Gynecol Endocrinol; 2005 May; 20(5):258-63. PubMed ID: 16019370
[TBL] [Abstract][Full Text] [Related]
8. Plasma homocysteine in polycystic ovary syndrome: does it correlate with insulin resistance and ethnicity?
Wijeyaratne CN; Nirantharakumar K; Balen AH; Barth JH; Sheriff R; Belchetz PE
Clin Endocrinol (Oxf); 2004 May; 60(5):560-7. PubMed ID: 15104558
[TBL] [Abstract][Full Text] [Related]
9. Fibrinolytic dysfunction in insulin-resistant women with previous gestational diabetes.
Farhan S; Winzer C; Tura A; Quehenberger P; Bieglmaier C; Wagner OF; Huber K; Waldhäusl W; Pacini G; Kautzky-Willer A
Eur J Clin Invest; 2006 May; 36(5):345-52. PubMed ID: 16634839
[TBL] [Abstract][Full Text] [Related]
10. Adiponectin is independently associated with insulin sensitivity in women with polycystic ovary syndrome.
Spranger J; Möhlig M; Wegewitz U; Ristow M; Pfeiffer AF; Schill T; Schlösser HW; Brabant G; Schöfl C
Clin Endocrinol (Oxf); 2004 Dec; 61(6):738-46. PubMed ID: 15579189
[TBL] [Abstract][Full Text] [Related]
11. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome.
Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D
Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808
[TBL] [Abstract][Full Text] [Related]
12. Body fat composition and distribution in women with polycystic ovary syndrome.
Cosar E; Uçok K; Akgün L; Köken G; Sahin FK; Arioz DT; Baş O
Gynecol Endocrinol; 2008 Aug; 24(8):428-32. PubMed ID: 18850379
[TBL] [Abstract][Full Text] [Related]
13. Adiponectin levels in women with polycystic ovary syndrome and severe insulin resistance.
Sepilian V; Nagamani M
J Soc Gynecol Investig; 2005 Feb; 12(2):129-34. PubMed ID: 15695109
[TBL] [Abstract][Full Text] [Related]
14. Is prostate-specific antigen a potential new marker of androgen excess in polycystic ovary syndrome?
Vural B; Ozkan S; Bodur H
J Obstet Gynaecol Res; 2007 Apr; 33(2):166-73. PubMed ID: 17441890
[TBL] [Abstract][Full Text] [Related]
15. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome.
Shi Y; Guo M; Yan J; Sun W; Zhang X; Geng L; Xu L; Chen Z
Neuro Endocrinol Lett; 2007 Dec; 28(6):807-10. PubMed ID: 18063948
[TBL] [Abstract][Full Text] [Related]
16. Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia.
Sebestjen M; Zegura B; Guzic-Salobir B; Keber I
Wien Klin Wochenschr; 2001 Feb; 113(3-4):113-8. PubMed ID: 11253736
[TBL] [Abstract][Full Text] [Related]
17. Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation.
Mertens I; Ballaux D; Funahashi T; Matsuzawa Y; Van der Planken M; Verrijken A; Ruige JB; Van Gaal LF
Thromb Haemost; 2005 Dec; 94(6):1190-5. PubMed ID: 16411393
[TBL] [Abstract][Full Text] [Related]
18. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
[TBL] [Abstract][Full Text] [Related]
19. A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome.
Moran LJ; Hutchison SK; Meyer C; Zoungas S; Teede HJ
Clin Sci (Lond); 2009 May; 116(10):761-70. PubMed ID: 18851710
[TBL] [Abstract][Full Text] [Related]
20. Serum total L-carnitine levels in non-obese women with polycystic ovary syndrome.
Fenkci SM; Fenkci V; Oztekin O; Rota S; Karagenc N
Hum Reprod; 2008 Jul; 23(7):1602-6. PubMed ID: 18378560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
